Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Cellular Signalling|May 28, 2013
Involvement of small GTPase RhoA in the regulation of superoxide production in BV2 cells in response to fibrillar Aβ peptidesMi-Young Moon, Hee-Jun Kim, Yi Li, et al.
Cancers|November 10, 2020
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)Soohyeon Lee, Seock-Ah Im, Gun Min Kim, et al.
BMC Cancer|November 3, 2007
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerBhumsuk Keam, Seock-Ah Im, Hee-Jun Kim, et al.
Cancer Research and Treatment|February 21, 2018
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)In Hae Park, Seock-Ah Im, Kyung Hae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
Breast Cancer Research and Treatment|September 13, 2008
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapyBhumsuk Keam, Seock-Ah Im, Hee-Jun Kim, et al.
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Cancer Medicine|July 30, 2019
Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03Woo Kyun Bae, Hyo Jin Lee, Se Hoon Park, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
Pageof 17